|
1
|
Ang TL and Fock KM: Clinical epidemiology
of gastric cancer. Singapore Med J. 55:621–628. 2014. View Article : Google Scholar
|
|
2
|
Song H, Ekheden IG, Zheng Z, Ericsson J,
Nyrén O and Ye W: Incidence of gastric cancer among patients with
gastric precancerous lesions: Observational cohort study in a low
risk Western population. BMJ. 351:h38672015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen G, Xu M, Chen J, Hong L, Lin W, Zhao
S, Zhang G, Dan G and Liu S: Clinicopathological features and
increased expression of toll-like receptor 4 of gastric cardia
cancer in a high-risk chinese population. J Immunol Res.
2018:71328682018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
He J, Qi H, Chen F and Cao C: MicroRNA-25
contributes to cisplatin resistance in gastric cancer cells by
inhibiting forkhead box O3a. Oncol Lett. 14:6097–6102.
2017.PubMed/NCBI
|
|
5
|
Silberman H: Perioperative adjunctive
treatment in the management of operable gastric cancer. J Surg
Oncol. 90:174–187. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Luo Y, Cui S, Tang F, Shen C, Qi Y, Lu D,
Ma L, Yang Y, Li Y, Chen R, et al: The combination of crocin with
cisplatin suppresses growth of gastric carcinoma cell line BGC-823
and promotes cell apoptosis. Pak J Pharm Sci. 30:1629–1634.
2017.PubMed/NCBI
|
|
7
|
Lai KW, Koh KX, Loh M, Tada K, Subramaniam
MM, Lim XY, Vaithilingam A, Salto-Tellez M, Iacopetta B, Ito Y, et
al: Singapore Gastric Cancer Consortium: MicroRNA-130b regulates
the tumour suppressor RUNX3 in gastric cancer. Eur J Cancer.
46:1456–1463. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Xu Y, Zhao F, Wang Z, Song Y, Luo Y, Zhang
X, Jiang L, Sun Z, Miao Z and Xu H: MicroRNA-335 acts as a
metastasis suppressor in gastric cancer by targeting Bcl-w and
specificity protein 1. Oncogene. 31:1398–1407. 2012. View Article : Google Scholar :
|
|
9
|
Chang L, Guo F, Wang Y, Lv Y, Huo B, Wang
L and Liu W: MicroRNA-200c regulates the sensitivity of
chemotherapy of gastric cancer SGC7901/DDP cells by directly
targeting RhoE. Pathol Oncol Res. 20:93–98. 2014. View Article : Google Scholar
|
|
10
|
Nan YH, Wang J, Wang Y, Sun PH, Han YP,
Fan L, Wang KC, Shen FJ and Wang WH: MiR-4295 promotes cell growth
in bladder cancer by targeting BTG1. Am J Transl Res. 8:4892–4901.
2016.PubMed/NCBI
|
|
11
|
Shao M, Geng Y, Lu P, Xi Y, Wei S, Wang L,
Fan Q and Ma W: miR-4295 promotes cell proliferation and invasion
in anaplastic thyroid carcinoma via CDKN1A. Biochem Biophys Res
Commun. 464:1309–1313. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jiang J, Yuan Z, Sun Y, Bu Y, Li W and Fei
Z: Ginsenoside Rg3 enhances the anti-proliferative activity of
erlotinib in pancreatic cancer cell lines by downregulation of
EGFR/PI3K/Akt signaling pathway. Biomed Pharmacother. 96:619–625.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang X, Song Q, Wei C and Qu J: LRIG1
inhibits hypoxia-induced vasculogenic mimicry formation via
suppression of the EGFR/PI3K/AKT pathway and
epithelial-to-mesenchymal transition in human glioma SHG-44 cells.
Cell Stress Chaperones. 20:631–641. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang B, Jiang H, Wang L, Chen X, Wu K,
Zhang S, Ma S and Xia B: Increased MIR31HG lncRNA expression
increases gefitinib resistance in non-small cell lung cancer cell
lines through the EGFR/PI3K/AKT signaling pathway. Oncol Lett.
13:3494–3500. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Han BH, Lee YJ, Yoon JJ, Choi ES, Namgung
S, Jin XJ, Jeong DH, Kang DG and Lee HS: Hwangryunhaedoktang exerts
anti-inflammation on LPS-induced NO production by suppressing MAPK
and NF-κB activation in RAW264.7 macrophages. J Integr Med.
15:326–336. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jiang Q, Wu C and Zhang Q: microRNA-34a
participates in lipopolysaccharide mediated sepsis related renal
function impairment via Kruppel-like factor 4. Zhonghua Wei Zhong
Bing Ji Jiu Yi Xue. 30:351–354. 2018.In Chinese. PubMed/NCBI
|
|
17
|
Mondal J, Samadder A and Khuda-Bukhsh AR:
Psorinum 6x triggers apoptosis signals in human lung cancer cells.
J Integr Med. 14:143–153. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cimas FJ, Callejas-Valera JL,
Pascual-Serra R, García-Cano J, Garcia-Gil E, De la Cruz-Morcillo
MA, Ortega-Muelas M, Serrano-Oviedo L, Gutkind JS and
Sánchez-Prieto R: MKP1 mediates chemosensitizer effects of E1a in
response to cisplatin in non-small cell lung carcinoma cells.
Oncotarget. 6:44095–44107. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kang Y, Nagaraja AS, Armaiz-Pena GN,
Dorniak PL, Hu W, Rupaimoole R, Liu T, Gharpure KM, Previs RA,
Hansen JM, et al: Adrenergic Stimulation of DUSP1 Impairs
Chemotherapy Response in Ovarian Cancer. Clin Cancer Res.
22:1713–1724. 2016. View Article : Google Scholar :
|
|
20
|
Cortes-Sempere M, Chattopadhyay S, Rovira
A, Rodriguez-Fanjul V, Belda-Iniesta C, Tapia M, Cejas P,
Machado-Pinilla R, Manguan-García C, Sánchez-Pérez I, et al: MKP1
repression is required for the chemosensitizing effects of
NF-kappaB and PI3K inhibitors to cisplatin in non-small cell lung
cancer. Cancer Lett. 286:206–216. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang Q, Shi S, He W, Padilla MT, Zhang L,
Wang X, Zhang B and Lin Y: Retaining MKP1 expression and
attenuating JNK-mediated apoptosis by RIP1 for cisplatin resistance
through miR-940 inhibition. Oncotarget. 5:1304–1314. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang X, Xiao Q, Xing X, Tian C, Zhang H,
Ye F, Wan F, Wang B, Guo D and Lei T: LRIG1 enhances cisplatin
sensitivity of glioma cell lines. Oncol Res. 20:205–211. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cao W, Yang W, Fan R, Li H, Jiang J, Geng
M, Jin Y and Wu Y: miR-34a regulates cisplatin-induce gastric
cancer cell death by modulating PI3K/AKT/survivin pathway. Tumour
Biol. 35:1287–1295. 2014. View Article : Google Scholar
|
|
24
|
Cheng C, Qin Y, Zhi Q, Wang J and Qin C:
Knockdown of long non-coding RNA HOTAIR inhibits cisplatin
resistance of gastric cancer cells through inhibiting the PI3K/Akt
and Wnt/β-catenin signaling pathways by up-regulating miR-34a. Int
J Biol Macromol. 107:2620–2629. 2018. View Article : Google Scholar
|
|
25
|
Hu B, Zhang H, Wang Z, Zhang F, Wei H and
Li L: LncRNA CCAT1/miR-130a3paxis increases cisplatin resistance in
non-small-cell lung cancer cell line by targeting SOX4. Cancer Biol
Ther. 18:974–983. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li N, Yang L, Wang H, Yi T, Jia X, Chen C
and Xu P: MiR-130a and MiR-374a function as novel regulators of
cisplatin resistance in human ovarian cancer A2780 cells. PLoS One.
10:e01288862015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li NW, Wang HJ, Yang LY, Jia XB, Chen C
and Wang X: Regulatory effects and associated mechanisms of
miR-130a molecules on cisplatin resistance in ovarian cancer A2780
cell lines. Sichuan Da Xue Xue Bao Yi Xue Ban. 44:865–870. 2013.In
Chinese.
|
|
28
|
Łukaszewicz-Zając M, Szmitkowski M,
Litman-Zawadzka A and Mroczko B: Matrix metalloproteinases and
their tissue inhibitors in comparison to other inflammatory
proteins in gastric cancer (GC). Cancer Invest. 34:305–312. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang H, Jiang Z, Chen H, Wu X, Xiang J and
Peng J: MicroRNA-495 inhibits gastric cancer cell migration and
invasion possibly via targeting high mobility group AT-Hook 2
(HMGA2). Med Sci Monit. 23:640–648. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Capes-Davis A, Theodosopoulos G, Atkin I,
Drexler HG, Kohara A, MacLeod RA, Masters JR, Nakamura Y, Reid YA,
Reddel RR, et al: Check your cultures! A list of cross-contaminated
or misidentified cell lines. Int J Cancer. 127:1–8. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mraz M and Pospisilova S: MicroRNAs in
chronic lymphocytic leukemia: From causality to associations and
back. Expert Rev Hematol. 5:579–581. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li X, Zheng J, Diao H and Liu Y: RUNX3 is
down-regulated in glioma by Myc-regulated miR-4295. J Cell Mol Med.
20:518–525. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Choi E, Lantz TL, Vlacich G, Keeley TM,
Samuelson LC, Coffey RJ, Goldenring JR and Powell AE:
Lrig1+ gastric isthmal progenitor cells restore normal
gastric lineage cells during damage recovery in adult mouse
stomach. Gut. 67:1595–1605. 2018. View Article : Google Scholar
|
|
34
|
Ueda T, Volinia S, Okumura H, Shimizu M,
Taccioli C, Rossi S, Alder H, Liu CG, Oue N, Yasui W, et al:
Relation between microRNA expression and progression and prognosis
of gastric cancer: A microRNA expression analysis. Lancet Oncol.
11:136–146. 2010. View Article : Google Scholar
|
|
35
|
Miao J, Wu S, Peng Z, Tania M and Zhang C:
MicroRNAs in osteosarcoma: Diagnostic and therapeutic aspects.
Tumour Biol. 34:2093–2098. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Saikawa Y, Kubota T, Kuo TH, Kase S,
Furukawa T, Tanino H, Ishibiki K and Kitajima M: Synergistic
antitumor activity of mitomycin C and cisplatin against gastric
cancer cells in vitro. J Surg Oncol. 54:98–102. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kania J, Konturek SJ, Marlicz K, Hahn EG
and Konturek PC: Expression of survivin and caspase-3 in gastric
cancer. Dig Dis Sci. 48:266–271. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yang M, Shan X, Zhou X, Qiu T, Zhu W, Ding
Y, Shu Y and Liu P: miR-1271 regulates cisplatin resistance of
human gastric cancer cell lines by targeting IGF1R, IRS1, mTOR, and
BCL2. Anticancer Agents Med Chem. 14:884–891. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Duan H, Qu L and Shou C: Activation of
EGFR-PI3K-AKT signaling is required for Mycoplasma
hyorhinis-promoted gastric cancer cell migration. Cancer Cell Int.
14:1352014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhang W, Tan Y and Ma H: Combined aspirin
and apatinib treatment suppresses gastric cancer cell
proliferation. Oncol Lett. 14:5409–5417. 2017.PubMed/NCBI
|
|
41
|
Luo J, Manning BD and Cantley LC:
Targeting the PI3K-Akt pathway in human cancer: Rationale and
promise. Cancer Cell. 4:257–262. 2003. View Article : Google Scholar : PubMed/NCBI
|
